TMO - Earnings call transcript Q4 2017 | Thermo Fisher Scientific Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2017 Fourth Quarter Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. I would like to introduce our moderator for the call, Mr. Investor President, Vice Apicerno, Relations. Kenneth Mr. begin Apicerno, call. you may you

Kenneth Apicerno

for morning and us. you thank Good joining

earnings with copy is archived Senior me our President call live thermofisher.com, note, the Presentations, On today available being Investors is until XXXX. heading Investors XXXX A Executive Chief Officer. & webcast and fourth section this and is call and the will of February Financial Marc Officer, release Webcasts of Stephen future the heading under press President Williamson, in our be Vice and Financial section Please website, on Chief our website the Casper, expectations of Results. and quarter under XX, the our the of

Harbor factors, is as the and quarter the those the XXXX in that may under available Litigation result statements Harbor may Exchange those So, of indicated of before we the website by the future SEC begin, XX, section and Company’s ended our for important materially Safe XXXX. Factors, Securities for from Actual let prospects quarterly including Form under with Safe heading Various various of Company’s September make forward-looking discussed in the Risk purposes caption we then also under on statement. me constitute statements about report provisions plans, these Private on file our briefly and expectations, the forward-looking differ a Act of which the remarks XX-Q Reform Commission Securities the Investors results cover Filings.

most today. even as views XXXX and any directly on in the the to during of should GAAP. these the this available is financial comparable or we’ll elect under obligation and Financial certain referring the statements in prepared fourth these change. Therefore, expectations A also Generally GAAP rely Information. to Accepted future, disclaim press you Also, measures non-GAAP earnings call, financial specifically date as quarter point if measures future forward-looking may accordance our some of in estimates forward-looking in update reconciliation to of statements subsequent to measures any heading our we our While not to with be of release representing website do Accounting the so, section Principles, not we Investors at our

call So, with turn that, Marc. I’ll now to the over

Marc Casper

joining Thank XXXX for for QX you, Good Thanks us Ken. our everyone. morning, call. today

conditions by you has executed our The earnings; strong successfully very well we press for As strengthened strategy and partner saw in made our customers for completing we ahead. executing significantly in we progress and our a across stronger XXXX and became achieved position good take and sets an M&A. leadership our year release, in our growth up the well outstanding excellent we We strategic revenues delivered end-markets; to of year. advantage growth

We have to this lot morning. a cover

I So, and the from highlights will the quarter hit the of just some year.

performance, increase with Let adjusted with per share to our strong with very QX $X.XX share. We delivered quarter. growth in me begin per a the financial earnings XX% starting

Adjusted XX.X%. operating consistently increased strong $XX.XX year to revenues We billion. share increased margin for XX% billion to billion Adjusted extended our Our performance full operating the operating adjusted our with revenue and per income track of XX%. result increased adjusted to year. XX% record was $X.XX our XX% QX to year-over-year to XX% earnings a increased in $X.XX long earnings XX% margin quarter XXXX per the Turing to of full the $X.XX in $X.XX adjusted operating in billion. for increase with in income by We share. delivering

a was it So, year. great

and driving of integrating initiatives growth job successfully our and forward excellent an completing new did team Our acquisitions.

our for for we’re of efforts, our customers, to opportunities shareholders. serve provide stronger As position our create in a result their collogues value a and

commentary the by Turning year. our of for pharma give quarter strong on our growth some delivered including all in with in bioproduction market. to and strong growth I businesses. serve these additional opportunities. were This results specific clinical a from color businesses our we this will our that the contributions across end QX very end you in good biotech. the to for executed Starting trials performance and advantage take on and market. Conditions We customers and well growth XX% our resulted of quarter little

the of unique pharma We our relationships capitalize to the these on over customers. proposition continue to and built we’ve deep and strength deliver underlying biotech value time for

digit the high our high we across In demand a key the mass microscopy this we a from in digits single and perspective, single and and Our electron end led position year. during government, market, performed well saw academic we strong systems. regions; for leading product the Geographically, our spectrometry for growth in to grew quarter.

to delivered single we In we year, digit pleased full end digit growth diagnostics single deliver mid high with good very growth. the a care, For quarter were in and health this market.

biomarker Our market performance was demand seasonal by as in businesses primarily for in strength good our tests. our well driven as end this

strength good our serving customer here analysis base. Last, our our great was In the achieved applied, In various and quarter business. the single For the we growth particular, across this year, in industrial chemical full continued mid year. see was growth growth in and digit it in the digits. businesses QX, we to low for single saw

across led So, board to for Good and year. execution growth our summarize the performance. to by strong teams great our market the conditions

innovative core leverage accomplishments million all we deliver high we of made shift innovation. emerging key our unique to our markets me in of proposition pleased value is all the as with $XXX a in strategy. new our progress and milestones excellent to continuously elements highlights. XXXX about in in our of the a scale is about let strategy, cover technology of Company, a the during Now, platforms, growth to the across am some year We our context I had R&D, our of and values our which talk going three I’m Starting our develop with on to one invested in of XXXX. in This products, based customers. gears number impact, and ability

the spectrometry. First, mass

build We the our system HF-X success long-term life Exactive platform Thermo research. the continued for Q Scientific of launching on sciences Orbitrap by to

We also instruments. the new triple-stage for for markets offering applied quadrupole our expanded

biology, Turning Scientific us Thermo then, to new science electron to fast-growing and little DualBeam that for we since Thermo our such for It’s been number a material presence and microscopy. the over are our expanded Krios systems market. FEI, new a year helping GX since GXi in structural Scientific our launched as Helios platform highlights increase applications, we acquired products we of among

expand the to recall of in Specialty Chemistry presence business You achieved new helping leading cryo-EM PCT year. clearance even the through XXXX our Diagnostics, biology of Nobel and is receiving In to we winners continue our our of bacterial structural the regarding This as doctors Prize antibiotics. the developments better in breakthrough pharma that test BRAHMS stronger a decisions included to make during assays This terrific that technologies. a a in use we FDA launched infection, make use the may using of number for biomarker biotech.

treating This technology. in us system new to low new priority immunotherapy exciting was non-small first highlights for the well laboratories. and which another Applied both that in forward. We as throughput Test; sequencing. for FDA-approved our affordability a enabled designed cloud-enabled most going examples of our breakthroughs mid FDA-approved to leukemia for cancer contributions Especially analysis Oncomine was simplicity the for business CAR-T medicine advancing first XXXX Sanger our in are through have One to diagnostic for was were significant Biosystems These NGS-based cancer using Dynabeads companion of treatment childhood the number which innovations. form our customers a genetic working significant two towards and instrument our was continue lung our SeqStudio a were cell of Target use will precision be Dx specific serve

second of the growth our strategy. element to Turning

We continue our to in markets. to scale drive emerging growth leverage

and revenue. As regions delivered remains of China of XXXX, total South all market XX% in again India, in XX% us, key Korea a constituting teens high-growth the and of today. growth. revenue high total strong these grew for about China, our once growth year-end our represent

during long-term We’ve capabilities in opened microscopy us helping centers investments. These are invested we significantly to are fuel electron new in outlined plan. through China year, continue our XXXX. We China in also capitalize in pleased digital to capabilities And and five-year grew new in showcased that China’s leadership on medicine. ecommerce demo the precision priorities revenues XX% our the that our growth customer and targeted two in the

In addition emerging Southeast across markets depth to scale to India Middle continued and to China, the Asia. of increase East from capabilities to our we’ve

strategic of microscopy We we small electron invested customer platforms. value acquisitions of proposition In our that element year. air through which our the enhance monitoring acquisitions is quality a to the completed our expand to scanning number and offering significantly strategy. Turning our during two bolt-on QX, third growth

As significant manufacturing to a our on to and super to excited is targets you a enthusiasm development customers. on impacted help logistics in them of met five the complement opportunities and they’re perfect to by year proceeding about months, recently to hurricane. I’d from as achieve leading our services integration their team of they contract I owned and services customers. business. power to They’re revenue create was is infrastructure $X and well, the reflection kick off for capabilities what the billion track leading part and one. update synergy know, after with provider you a island’s that Thermo cost our our for year. allowed site Patheon services believe the I of most trials acquisition pharma These Rico business biotech of We’ve have Patheon we’re the Fisher the us sales are this and about from Puerto Patheon, also pharma in our and pharma for XXXX damage was hearing the directly transaction biotech like clinical the a

of really site patients. facility getting our on shipping QX The in there way all help the I and of proud as and responded, stepped safe were late medicines more entered couldn’t line operational colleagues sure they we making teams began critical deliver up, was to and the their back customers fully Our be to XXXX.

strategic Turning told, billion M&A on our to XXXX to $X.X the of another we and Thermo strengthen All very us. year expand deployed offering customer deployment, Fisher. for capital was position active

have to active a continue we forward, M&A very pipeline. Looking

debt the focused on we’re made. returns to from driving investments committed and we’ve down paying high We’re

shareholders XXXX through We buybacks dividends. to $X billion also capital returned in and of our stock

dividend strategy. intend capital And As of XX%. to overall we our our in an dividend past, we time. over said we increased announced part by Returning grow deployment important morning, the we that our remains capital this

up, made we wrap announcement me the other morning. I on quick this comment let Before make a

tax around breakthrough rate. one-time new R&D and all some for XXXX, way the decided Thermo activities. benefit of $XX In know, paying you colleagues, and As the and our them commitment to world to for of to million our to we’ll non-executive further of a education million our reinvest We’ve invest in accelerate is colleagues the to positive our benefit the to customers real invested $XX tax lower and as the a tax thank bonus Fisher our we In will of communities. increase STEM by XXXX, impact sustainability success. their programs also a law

growth. We’re of this complement Fisher’s investments future opportunity take to advantage in pleased to our unique Thermo ongoing

So year. our a great capped off summarize, QX to really strong

gain deliver share. Our our growth. earnings our teams to advancing executed leadership revenue growth to by very We and strengthened and strategy strong continuing well

M&A customers strategy We shareholders. our also our significant continued successfully to our create value to and execute for

you’d to that quickly hit but the factor into the our financial extend guidance, outline ahead, performance consistent, XXXX. earnings long track our let highlights. Looking strong record expect, revenue of will Stephen me planning assumptions we’re as in and

billion deliver result In billion would our XX% expect to we XX% which terms to revenue, over of growth XXXX. in in $XX.XX XXXX to from $XX.XX

of XXXX per EPS for range $XX.XX would to to $XX.XX performance guidance EPS share. we This over strong this XX% adjusted initiating the past lead We’re the to XX% year. adjusted growth delivered in

Williamson. Stephen year us that, ahead. really successful over I our will call XXXX sets With turn in result for up another Stephen? excellent to the CFO, Our

Stephen Williamson

everyone. full take our detailed year Company, on of results I’ll our Marc, XXXX the with provide our segments, I’ll a good and you of four color review Thanks, guidance. and and then, some fourth total quarter morning, conclude through

our to into be how the our get fourth it the thought call. helpful level I of our of last high I details out versus expectations a played Before would quarter the financial performance, view earnings at time provide of

point, guidance. operational we our $XX a that we was earning pull-through in delivered the QX. you execution. bonus market As was finish environment, FX to driven X% the strong Company growth by previous was good collogues acquisition, share on an stand the From organic and and driven and per saw great our across year partially non-executive more press higher our from had This conditions that growth favorable delivered adjusted by release, million the good Patheon This $X.XX organic performance in and offset onetime the our Marc than highlighted. midpoint by of earnings for

So, for $X.X of growth year flow. adjusted as X% and billion a delivered in the organic we share free per XX% growth, whole, earnings cash

results So, overall, in excellent financial XXXX.

So, now, more per share. you performance. with our let me Starting on earnings give color adjusted

in As release, $X.XX. by press XX% you grew saw to our QX in adjusted EPS we

the $X.XX, was XXXX. year, full For up EPS adjusted versus XX%

guidance the on cover charge reform the impact This partially the of new will of corporate tax during the earnings on The offset impact the represents GAAP million. U.S. by expected, positive of have rates. you of As tax onetime comments $XXX legislation impact legislation of impact transition a deemed on. only detail quarter. enacted at lower it foreign in tax the Company. was U.S. tax QX a deferred balances repatriated on remeasurement was XXXX section in know, later will we the the my as XXXX I And subsidiaries,

As from was XXXX GAAP versus down EPS a was up XX% year $X.XX, XXXX. the in XX% quarter the for last and year result, $X.XX, full QX

top-line, foreign our organic QX XX% the increased The On growth revenue included in the tailwind reported X% of and impact from and revenue components XX% year-over-year. our acquisitions exchange. of QX, X%

reported X% includes from growth impact XXXX organic revenue increased foreign year-over-year. from impact immaterial For The the XX% acquisitions reported and X% and revenue an XXXX year, full exchange.

the Asia our which the digits, the North and world teens the teens, the in strong China grew in QX. geography in digits, Pacific grew high contribution low at grew Europe Looking the in by teens. of with growth low America in from grew rest mid another single grew high single

geographies full Pacific, which the grew For all year, for the Asia mid single XX%. in grew digits except

performance. XX% year. from operational last QX points XX%, to operating Turning adjusted income was margin our and of basis increased adjusted down XX operating QX

reminder, Patheon scale The and operating was basis average XX adjusted non-executive basis one-time to a our to margins XXXX gross points operating and The Company quarter. lower a dilutive just of continue As margins than in income is to margins Patheon over addition points was quarter. total a acquisition and margins of to will bonus the margins dilutive the operating adjusted cost be our operating payments over to our in first QX dilutive adjusted months XX XX the colleagues ownership. in by was with

quarter So, good our the driven unfavorable underlying at operational and strong strategic very of XX basis performance by partially offset by investments was business points productivity, and pull-through expansion, mix. in volume

line XX.X%, income was and expectations. increased full from the operating year, with our up XX% operating basis XX For adjusted margin XXXX, in adjusted points

basis at of details adjusted points XXX the Company the P&L. came XX% margin to from on prior quarter, down year. Moving the Total in gross the in

XXXX. basis For from points adjusted XX.X%, gross year, was margin the XX down full

XXXX, points and business QX quarter quarter down this driven down which Adjusted was dilutive the by impact expense full mix; basis productivity. of revenue, last of in R&D contraction XX XX.X% unfavorable the partially by in a acquisitions of the was basis and is the points strong margin offset at and versus both versus XXX year. of For X.X% QX was SG&A came year, gross revenue, of

R&D XX.X%, the manufacturing was XX the SG&A down of was was to XX percent sales, year, year compared XXXX, of full to the adjusted basis year, a expense and points For revenue year as points full up X.X%. for R&D and our prior compared basis X.X%

versus million expense last year primarily which mainly is expense million non-operating expense was year, the for higher the driven changes capital QX other this unfavorable our related million, $XXX in the of below as $XX was million, was deployment $XXX to result is debt The full million, results income $XX incremental the XXXX. a at net of interest QX FX. million net our which XXXX, and QX at an than a increase expense from quarter in Adjusted by in $XX $X activities year. interest line. Looking Net

quarter, timing rate tax basis-point tax of XXXX of as items planning the was is XX.X% in due our than lower QX XXX Patheon. this impact as discreet adjusted well in line a the prior guidance; with Our the right to

higher Our XX%, year rate full were full than higher is lower year points than to XXXX. basis was average XXX.X adjusted option which tax our diluted guidance due shares million, previous slightly XX slightly QX million of dilution. XXX

XXX shares million, million average full from For year, XXXX. X.X diluted were up the

For the income. FX the in on XXXX. adjusted $XX full an impact million $X.XX from had headwind resulting income headwind revenue on immaterial was EPS on operating a full year, tailwind a year, $XX in of adjusted and FX Other million for year-over-year FX

the flow Turning to cash balance and sheet.

full operations the flow that billion of than performance net and million For primarily was was $X.X XXXX of guidance, and due cash is $XXX free $X billion million ahead to operational effective management. expenditures deducting our continuing from cash year, previous and after flow higher capital strong $XXX working capital approximately

During XXXX $XXX million $XXX buybacks we dividends. shareholders continued returning in and of with capital share million to

$XXX We debt down slightly note to finished senior quarter. just preparing driven pay the the pay QX, during January. billion, $XX normal debt year by we Marc week the down from of including million acquisitions. strengthen of through All well $X.X As acquisitions billion. was in approximately successfully told, smaller cash, $X.X XXXX a billion mentioned, with proposition approximately number Patheon capital our strategic customer deployed to the bolt-on in with deployment than first were We capital value total total the end ended as as down of higher billion as a in our in we quarter $X

adjusted end down at times X.X basis, a the leverage year times the the end line which expectations. our QX and of reported was from ratio EBITDA total on at to in X of with debt Our is

ROIC my was our wrapping So, impact at is demonstrating drive acquisition points in to our this of of Adjusted significant XXXX. our strength XX we up activity total XX%; underlying basis the Company XXXX compared performance, comments, the year, ROIC the from end of prior the in performance capital offsetting to continued strong businesses XXXX. up a added

you segment, that, Life four growth XX% on starting revenue biosciences saw segment. business was bioproduction of Solutions QX. now and Reported increased revenue strong Sciences the color and organic in performance across provide growth with our businesses. the segments, with So, some We I’ll X% particularly in our

X% organic operating growth Life QX revenue For in X%. reported was the increased increased is revenue Solutions and year, operating and which was Sciences margin full XX.X%, adjusted income adjusted XX% XXX basis investments. as margin productivity operating strategic exchange; expansion this and QX driven XXXX. points higher well pull-through strong partially was than as offset volume of by by Adjusted foreign was

organic full basis revenue of across growth points year segment. benefited we growth from within quarter, XX.X%, operating margin all businesses strong Analytical increase In was our over the XX% In QX. XXXX, of the in this revenue reported XXXX. adjusted was segment, an XXX XX% the and increased Instruments contributions For

revenue Analytical impact XX% offset mix. in year, the the saw X%. productivity exchange we business foreign the the increased Instruments organic a operating pull-through; reported and year-over-year investments, income strong unfavorable full QX adjusted very at adjusted increased strategic In For XX.X%. was and volume by of in was operating was and margin growth segment this XX% and flat quarter,

XX.X%, margin increased full adjusted XXX adjusted was year operating higher points the XXXX. XX% income operating XXXX, For than basis and

diagnostics organic increased performance to our Turning had revenue growth and in X%. In growth businesses. in products and was seasonal quarter, XX% In clinical we segment. good reported the revenue the and transplant QX, strong Diagnostics Specialty

within Adjusted offset than contributions unfavorable our pull-through; benefited operating reported QX year. revenue the the in income Adjusted the down this and quarter business PPI margin from grew is however, of organic XX XXXX year, Business operating investments. points both For mix from volume compared operating basis strategic to prior was XX.X%, margin X% and System and positive more by and X%. grew full adjusted we

Services operating and segment, Patheon points organic which segment, the X% Products basis down For QX as finally, reminder, will and increased In acquisition. increased and was year reported XXXX. XX% margin XX was XXXX, growth Laboratory I adjusted income And this the the adjusted a full revenue includes from XX.X%, X%. operating revenue cover

and Our channel to organic this logistics all good businesses the growth see the business. growing trials from business strong once segment including quarter again well, clinical it’s delivered in

accretive adjusted and XX% full the For is impact from organic year. strong investments. and this basis Adjusted from increased the strategic down operating and volume XXX increased in by mix unfavorable on growth the operating benefited points the X%. segment income than margin XX% margin the operating was reported from prior year, revenue QX, segment offset adjusted more pull-through acquisitions; was XX.X%, business In and

like margin year review our X% For With full compared was increased to adjusted XXXX and the income that, down the the XXX basis prior XX.X%, guidance. points operating I XXXX, operating adjusted to details year. of would

to initiating $XX.XX, we’re XXXX XXXX. over $XX.XX guidance mentioned, is Marc adjusted EPS growth of which range As to XX% XX% a a

and In over terms to between of revenue for XX% billion of revenue, to growth. our $XX.XX guidance range we’re XX% growth is X% is expecting deliver organic to which XXXX, XXXX. billion, X% $XX.XX And

Let me guidance. cover factored into that key assumptions our we the now

approximately given currencies, FX. addition assuming months. X%. an to past average of a assume at impact million two revenue which of We’re of XXXX, This the This just of XX%, over that the tailwind $XXX We from EPS foreign the represent a through rates transactional FX X%. exchange translates this over or our just current mix and reflects pull is should this $X.XX over to positive potential Patheon of tailwind

the the impact to expecting points this margins in profile expansion We The so operating dilution. points basis will XXXX From expect XX Patheon’s XX anniversary late margin XXXX to lower deliver reflecting our as XXXX, XXXX. margin headwind, in we’re to year-over-year basis date the average of the growth in Company, contribute than XX of operating this performance. X% of still acquisitions operational is August. until overall Despite standpoint, revenue be dilutive mentioned is adjusted I completed in in will it to reported of an earlier, strong

range the million and $XXX to to primarily below took in higher $XXX for acquisitions than interest XXXX. expense on we result expect increases XXXX, as the be $XX million, line, rate in about in the we assumed a of Moving debt of net XXXX

For I’ve in increases the basis points per assumed guidance XXXX. purposes, that XX rate Fed quarter

assuming income an in be We’re immaterial expense expense will other net and XXXX.

positive as expected, the earlier, mentioned of tax I company. the for a U.S. is impact As reform

assuming in tax to As tax XX% land, income XXXX. compares in on the planning a XX%; P&L adjusted that U.S. we by are expect tax being XXXX, charge supporting the finalized law rate the be slightly of for tax incurred factoring an QX activities, our detailed we’re transition we expect cost. result, taxes But, impact in addition where in this we than regulations Treasury. to from tax lower And anticipate the XXXX, The new we based still no adjusted XXXX. the cash final cash of to wording for

million approximately in the Patheon. announced due expenditures to expected full million impact the is million capital that dividends, projects year The over to to the in to year to and funding approximately flow anticipate of approximately timing approximately cash higher earnings. customer towards the net we’re of terms of XXXX; assuming XXXX we increase $XXX $XXX this dividend shareholders we’ll XXXX capital $X.X capital in today. increase be increase mainly Free of earlier assuming deployment, be billion due And to reflecting CapEx. is through return We’re $XXX We $XX million is for of year. over this the receiving

million offering the completed share shares We XXXX, the diluted million, be primarily will XXXX, in average approximately the assumes range the of in the average will to second Our last during assume full in the $XXX million buybacks due XXX which we total year a also million to year. up XXX from equity guidance half that of estimate of of be year. X

continue and Our any does always for the phasing to acquisitions assumes we’ll or to as reduce touch cash that finally, not guidance to divestitures. wanted excess quarterly on assume use I And year. future debt

phasing the organic driven In to half by average slightly comps terms of in timing and This the of first the and year. QX in higher the is for we’re of the expecting be holidays than growth, year QX QX. revenue strong

out. when of ranges, of should the adjusted phasing most we the EPS each focus the terms total likely same the as EPS, view And the percentage year In you at we’re playing year. how interpreting look and our a you see on adjusted as in as expecting guidance always revenue midpoint XXXX as quarter on

So, we and XXXX. that, I’ll excellent delivered to the doing forward results back look same to summary, Ken. With the financial XXXX in turn in call in over

Kenneth Apicerno

Thanks, Stephen. to for are it we up open ready Operator, questions.

Operator

[Operator Peterson comes Instructions] Our ahead. first from Tycho go from JP Please Morgan. question

Your line open. is

Tycho Peterson

to I with growth there, obviously Marc, great start wanted biopharma, off XX%.

you about any little can then, flush Just good some And wondering a results you trends? if color, from provide more seen peers. comment We’ve bit commentary as any think budget January on Can dynamic? out we there? bioprocess, your

earlier So, can you guide heard last us we through kind of the that inventory destock year? noise

Marc Casper

with growth was XX%. biotech and very for fourth year, a had good single-digit year pharmaceutical the in high in We and the quarter Yes.

think a board, trials positive. very all we see, our customers logistics bring so and a also we bioproduction finished great with we’re very the macro we it The very did term And So, quarter, very tailwinds research grew, of business when really to gain share you we understand quarter the there. clinical value was really continue fourth across long year standpoint, business, I a about channel biosciences, analytical perspective. From the mid the the was the that strong above the for very for way the about And prospects like as got it’s a year business; I bullish bioproduction, way instruments, bioproduction growth. really average. and quarter from Company strong had good grew well; we strong; know,

Tycho Peterson

up driver there Services and being comment that follow-up was. Products Lab sequentially digits, here. that? I curious you just for high And maybe academic single think big the the just the what And then, had you called a step drove what on up Can

Marc Casper

The performance Lab a Products across strong Services, the very and of really all businesses.

Our to businesses channel business right. the trials And was to drivers the really had one our of good end sequentially, nice returned clinical year. logistic a big very growth,

plus XXXX. we’re first year a quarters in study a on a going based mentioned just cancelation As ago, late large to we difficult have three

that, So, once which saw great that was anniversaried nice to you we growth. business, returned tailwind,

probably that business. So sequential that’s biggest change the in

Tycho Peterson

on can And high comment just then, there. the single Okay. academic And I’ll you digit leave growth? it

Marc Casper

Yes.

good mass and our quarter. across segment. growth in of in really We key that strong and saw electron very saw geographies academic government in and microscopy the analytical particularly a instruments, good all So, was growth we spectrometry the

Operator

Your comes Please from Muken next Ross question ahead. Evercore ISI. from go

is open. Your line

Ross Muken

welcoming back I and appreciate with a guys morning whole organization the Good quarter. such good

the is markets But, and share pretty than top it’s new incrementally gaining it the quite XX healthy. feels technologies, XX And So, serve good momentum business like line. backdrop like the it or Marc, you better you or is been feels guys of kind of sort whether are end have on months to peers. mix obviously, doing macro your last still

this so, versus recent more some macro of And better line? the you the some kind the How of how, have really performance, of the of or the you when think of markets acquisitions about the organic organization’s sort hard of is to on are teasing work much sort out? some the of doing and results

Marc Casper

industrial really the that obviously, to turned So, growth. biggest the digit question. thanks mid in are back markets the and was And change applied good. Ross, And single end for XXXX

the the based industry, you we contribution the success we the last organic we if from we helps organic growth delivered the the out highlighted, over from have couple of year, years, that X% performing are So, benefited even of in last X% would growth. about strategy. think and growth stronger obviously much delivered on growth as I took you organic when And But, and FEI it.

execution. a good And it So, was the we had across strong really year really business.

really year, good analytical year good instruments business and when the it channel on our business, you a portfolio, had strength was at across another spend. look Our

of contributed and strong all So, a it’s those terms our strategy. up to factors in very of performance XXXX, another in step

Ross Muken

may on That’s being lot mean, And be focused just China, helpful. attention there. I of

another fantastic You year. guys had

into that the biopharma In there, kind guide. between are sort terms of as the sort thinking industrial XXXX comps side seeing next of trends what’s baked of in both you of the how year differentiating and you and about how we enter region assumption and are

Marc Casper

expect within major our We China Company. the continue fastest is to growing geography to that going be

is above of in X diagnostics the and and area, Our protection. healthcare book a is expanding strong. bill the applied environmental in food amount tremendous China markets, There was to momentum safety, interest

it’s the to bit as that’s while XXXX in alignment benefiting the we really start. with the is driving comparison will off well, strong recovery in from We’re the a team five-year good obviously plan but little the a a industrial growth. And challenging China, have obviously

Operator

Bruin question Your de from ahead. of Merrill Lynch. from comes Please Bank go America next Derik

Your line is open.

Derik de Bruin

question So, and one other just one. cleanup one

sort of you stronger, do as you sort -- have individual. the So, on out be catch-up, better. to being were you trying any can aggregate; season like they just contributions basically I’m flu this But, flushes? break model can like from don’t it figure hurricane sort the budget an to to thought QX, what of of QX out XXXX

Marc Casper

Yes.

small way might the amount it impact were the hurricane products So, no didn’t be a seasonal strong. noise. really I but significant a catch-up; and creating quarter, the in I QX real very The guess, characterized nothing we see

that’s end percentage really year-over-year good about the a and this year, our year. So, strength the about saw spending last the of slightly then a in customers, at point probably year it’s quarter was half by weaker

a of total in maybe, So, points. couple

Derik de Bruin

believe a Okay, sequencing And to. to going just I’m great. helpful. actually ask That’s Thanks. I’m going I really but DNA can’t you question

you an lot overall a it’s have made XXXX. been And -- following has of size news of product? we Illumina the ask in of been I what sort Can there the of sort with for provide update while do sort news sequencing how want guys business growing. has the drove I’m relationship since to to then, that of just on business of a And and the the us lot your AmpliSeq decision wondering been that? sort of You’ve like a business

Marc Casper

immuno-oncology, new The new beginning one which two panels, of focused course all feedback Derik, of revenue At X% order this product the kind just XXXX. our very positive. customers of under of had of on good on a sequencers, in we important; one and next on very growing year, products the is new focused It’s We’ve represents liquid terms is of of launches that business very obviously a gen is lot well. from early in of during announced reasonably sequencing, of magnitude. line a Oncomine the biopsy.

chemistries instruments. that new sequencers. to amplification a also so growth base launch decision We’re launching were that of we we for products, a of their them comfortable very the to they they base. can obviously is made install on with install good continue given chemistry large And regarded. fact supply that in And our our Terms combination have And it mark with Illumina the moves. And very chemistry felt of that’s we opportunity. well those we like

Operator

comes from question and Cowen Please Schenkel from ahead. Company. go next Your Doug

open. line Your is

Doug Schenkel

built, the open based out getting today? net this about EBITDA I fair how that high XXXX X the currently in impact close typical certainty, where ROI does right here, the So, end M&A how application times debt we for how on law, see acquisition, of capacity, year. And so, X criteria the the to continue say by multiparter your for below a guess, you do is environment? closed think of sheet on it you’re ratio and balance about should valuation if the Is tax with times, as we think your to to that business your environment, we your

Marc Casper

Yes.

of of the time, the being we ourselves open We’re that, Company. one pipeline. issued as the in -- And of because at equity we take time, the this only a that part of level level we narrow would Patheon really market we’ve been integration some point the of the business modest never was But, have out for part is so active Patheon acquisition part reason never financed and we closed. very way here

push through So, to we the bandwidth we good felt opportunities. like had management

really substantial we’re of mode. have in And so, capacity. that We amount a

size constrained I from in So, feel of terms deal don’t financially that perspective.

In meaning work drive transaction the focus valuations ensure when downside terms and of if on of something good even bad the are do scenario say criteria really that you’ve we we doesn’t we have don’t on heard always used that ROI that higher, transactions, the transactions, me to returns, the as in past, we’re out. going

looking it and kinds does for is nose at ownership a that we M&A. that double a about, cycle in of example speculative So, was of this around transactions a that’s part kind businesses. it good if it do to of and market. of digits. business And it’s strong in years it, thinking it growing understanding in look great we at a avoided grow we FEI business first the able bought where type transactions, the we at of where you have bought the really And the we inform the X%, we were year spent

returns that So, we’ll we buy the things going on all are with our under to make shareholders feel scenario good that scenarios different downside understand we for and ROI possible. the are

Doug Schenkel

want topics addressed I up to back Q&A in just completely to think but two I the session came earlier And go clearly. that were don’t

are be there that the largely based industry pull far XXXX, QX? out bioproduction was the question to what forward into on just clear, you’re across earlier XXXX, the QX meaningful no First, thus was that dynamic you expense in in that’s there of the revenue abated? you on confident are that of seeing And confident of at destocking,

Marc Casper

heard say that never I’ve question. So, to someone answer

first. a that’s So,

year’s our at start year, they I the to last a were how When above guess, were I with Doug, consistent guidance. good off bookings the look X. for So,

a So, the with that there’s of or meaningful. started something and nothing would customer we indicate pull good forward about enter unusual the how year sort backlog, that year some was

that’s view. think the I So,

and forward is business say out a activity very business don’t would movements in and a push long there that I we’ve time. very, around the intellectual quarter-to-quarter had shouldn’t pipeline spend pull In very time. energy good the because lot terms of really customers bioproduction, positive. What year the is really the strong, orders customer been a all for it’s of We a is

XXXX outlook don’t business the the we that It’s quarter lumpy up or end about get too sign. strong for and said for and as long-term like But, feel the why excellent business I really on hung for and good So, good as mid-term that’s a us. we was a weak. feel look

Operator

comes Your Barclays. go Jack ahead. from next Meehan Please question from

line open. is Your

Jack Meehan

on all And since Patheon. just give the an outsourcing Thanks. traction you I has there Good synergies? of us then, beginning at morning, Could the the acquisition, to changed reform? on start the guys. discussions with wanted with tax the with revenue since customers year update dialogue

Marc Casper

Yes. Jack, the morning. for thank good question, you

we of having process a customers. quickly there’s terms is and the performance services long doesn’t been feedback a our But pharma early transfer achieved customer already that between capabilities. dialogue sort. new feedback a tech synergies we’re This business of trials the nonetheless, In clinical good of some meaningful has with is services products, of incredibly of and business revenue terms synergy very business Patheon, logistics the positive or -- number that turn have getting work our and things revenue in and

they will up over are time. those So, and happening ramp

of bioproduction business interesting as business the have really on portion We work our that biologics going with and well.

that So, we’re revenue bullish the business. for midterm the outlook about very growth in

a I compelling. of opens up tax strategy were longer have therefore, advantages think opportunities are to the over strategies really lot change possible jurisdictions that no pharmaceutical tax as customers new about the some through side to low those which how in of tax And plants their putting manufacturing does the On it’s of because the think law the of equation, their older time.

continue we explore So, something to will that our customers. that’s with

Jack Meehan

could X%, That’s the areas a back, And portfolio FEI of moving just you step growing organic momentum target I faster with if ended term you in growth to and XXXX lot Patheon. of long is have Great. with helpful. X and

Just the you and guidance today? to the sit that how here of are would as of you puts X% frame X what some context in and takes

Marc Casper

Yes.

about good obviously feel like we growth. quarter for way is the way year about The year, obviously thought about are, orders guidance adjust the the pay about we we felt going as And like felt markets challenging we guidance. is, it outlook the year the -- to we’re we good later X% we we the organic the a year attention will we’ve because to our year-end. the think end to X fourth unfolds, for the like ended, as in comparison have the of As the well. the initial We that way things

as spend year-end normal a opposed the in we’re So, very to year-end guidance spend. the strong assuming

well. factors. one growth that’s that which continues then, going to not one GDP know obviously And to we’re to be fourth be quarter, the would the So, around until if obviously, appears but accelerating of be accelerate, be direction. would that tailwind way it would could the flip opposite headwinds be the as be other world a it things what goes you would And could in that obviously if the on

Operator

Your next go Stanley. ahead. Steve from Please Morgan Beuchaw question comes from

Your open. line is

Steve Beuchaw

business. First question to is with instruments analytical the regard

saw end of what nice It How retrospective. you the of you year us a including then, there color product that new how you’re saw to benefit we’re And would thinking of on it for is be any sustainability but FDI flow? business some component, only in can talk those the the you give significant through half which of in business. with improvement of helpful, helpful, to pick-up how is XXXX, organic the can and much could be this organic a markets You much Thanks. the really about divers of because sort second would a recently. if of pretty profile regard modeling in not the be

Marc Casper

will then forward. terms back, looking I So, and of looking talk in

portfolio. obviously we across the new Looking products good had back in the second half,

mass So, contributor, electron well. as a that’s microscopy big beneficiary, spectrometry

The in very our good. chemical represents half second is industrial which handheld business, particularly cycle our instruments, other analysis was portable kind thing of short recovery,

the terms in the year of instruments base half. the broad very was second it in business growth the throughout and So, and

to electron had That and As a Company it. year. I think a this to average and comparison the growth strong business We that of the think had how our challenging for very grow be strong course the this about growth our above FEI about will FEI makes contributor growth; XXXX. microscopy XXXX anticipate very and in during year.

we think not see because and we spectacular obviously it, of the on into contributor big of based XXXX, but how it’s XXXX, as about momentum a So, would comparison. continuing

Steve Beuchaw

what in working do could guidance of you growth underlying potentially? quarter us flow? year-on-year speak And is impacted items, Stephen, is, could embedded cash for that all a couple you how then, what quarter fourth housekeeping at just impact Puerto in the free sense assumption capture wonder in first Patheon, of back some then, some that the the the of was any the capital if give And challenges of and I we Rico outlook one for

Marc Casper

to numbers terms we that’s little We -- Patheon but big had that but you wouldn’t QX But, obviously believe form bit of uptick during particularly of the for a bought course if so in rates. year-over-year I normal the we point. Underlying pickup a product will products In likely the Rico, customers source, at not factor. see our XXXX, a at they growth had business. big mid other in see year, Puerto for think of growth that source the for single the business may that digit effectively don’t

So, solid obviously growth here and headwind. had they

So, performance good there. about I feel

Stephen Williamson

the for In in the it of XXXX, difference not terms significant level, there. organically X% grow the a to norm assumption working of is working capital so expecting capital essentially business at need kind for normal to X% of a year

Operator

Your next Patrick question Sachs. Please ahead. from go from Goldman comes Donnelly

open. is line Your

Patrick Donnelly

I contribution? year assuming ago, following that Marc up preventing up you number, X getting macro know markets end rate, you’ve been. of about growth on market setup, and the long-term organic recall full the you upper past, from as just shot you Do XXXX talked a the they’ve But, X% are noted X. weeks one always has about to current you as towards question few headwind, a end in the can the In current holds getting end. you view Jack’s best towards healthy been the Maybe have as FEI backdrop

Marc Casper

outlook. position. Every year, of good into on we X% X% the X%. year generally organic historically, And Company the to growth; go as strategic feel and and the around obviously, been opening the working about the our strengthen this we’re did view as we’ve to we we always And year, maximize performance

year; possible best And doesn’t this of drive reflects the contributor not performance. flow months a our it momentum. it year. we’ll until big So, final the to the four Patheon in the organic to is growth

growth going not year. So, it to this is contribute, organic to contribute meaningfully while it’ll

in really growth. up where we’ll to going and winds strong ultimately quarters, that we’re see So, deliver four terms organic of

Patrick Donnelly

Amazon you this speak got a new. your results could to for business. And a particularly more but quarter, just themselves spite some being presence past It LPS would on the that’s like seems color provide air degree to if appreciate maybe their not threat little your time then, of obviously, in

the from So, market have them, are would any We different? your seen change expecting anything you thoughts? you appreciate in

Marc Casper

that a fluids, aggregating take taken very they a the way logistics, do our providing day, Amazon, largely Amazon of hazardous this on-site very different refrigeration, a supplies. we and seriously it web to that. customers reasons amazing a with us. to of cost relationships. We extraordinarily over a tried seriously, many unsuccessful, effective it lot heard me have And we’ve of In productivity, and for for we for market, And world-class I personnel in relentlessly an customers to we’re been handling it complex job make And and products, supplier for you customers. scientific as years difficult built the thought great they’ve have easy we’re of doing that job transact last say, drive at end the extraordinarily the set think reasons there’re right? is categories, technically our about capability five And focused on great the of for very of we’ve things great our

seriously. take we’ll it So, very

strong on we’ve of Amazon. in from channel performance our momentum business seen the great the couple have last and We note. And ended years had

but continue our about we’ll it, feel attention to good So, to position. pay competitive

Patrick Donnelly

Very helpful. Thanks.

Marc Casper

just Operator, we have more. time one for

Operator

Okay.

from Arias comes ahead. Citigroup. next Please Your question from go Dan

line open. Your is

Dan Arias

following it but continuing just whether up could in this your year? we XXXX? so your good some so out fiscal as land like assumption Obviously speak, on to live base feels case, kind in going there, Marc, while, NIH funding wondering of academic, for for legislation a U.S. just up what’s funding also resolution

Marc Casper

the for in we’re to outlook the our digit low and assuming for academic growth. single of year, guidance terms government In mid

biotech, environment to modest the be budget point end with gets recently. mid that And chance and single and NIH the time meet they’re have the of a in get digit; think year. did have depends mid expect for I leadership that segment holistic for the budget we just operating passed. low to stable on assuming markets, range care, We’re between in at in over digit. about will you this when a a some we’re digits, gets assuming under get mid why level when year kind better. we’re view year; passed, digit industrial, that’s single diagnostics we’re low single growth. a the a that there’d gives And of single and budget I If of health and to you also growth assuming pharma assuming and other mid it should high the It a

Dan Arias

the Yes. great. to is comp what XXXX? for the are LPS mid And Thank just just It you’ll Stephen, what obviously be getting necessary looks factors fundamentally then up for more be up one against Stephen. but back maybe key you. favorable to like in margin That’s teens. wondering a to

Stephen Williamson

driver. been has this well; principal businesses been has I year around So, are business change; the think mix individual driving doing really been the it’s the

You’re benefit from for date going margins the to anniversary Patheon see the actually from equation. the of LPS side through

the are I underlying businesses So, well. actually doing guess

Marc Casper

obviously, thank we end his wish of our me in retirement a the excellent General as And retiring with let Counsel Fisher the for hand for silent Company. Thanks, us position the long everyone. service So, years, interacting of for And Seth of course a I’d was the reflection him to wrap for management you thank year. been put Hoogasian, an Counsel achieve a our great the our then happy General XXXX to during a growth who’s is has quarter. the year, XX for the the to which first time. goals the the He’s than call of year like him the at of and the of the I And support and period And up with look right of you year. ongoing Thermo Scientific. team thank always, quick of comments, couple forward more for to been

Operator

conference call. concludes today’s This

may now disconnect. You

Thermo Fisher Scientific (TMO) 31 Jan 182017 Q4 Earnings call transcript